Preliminary Success Against Eye Disorders Renewing Interest In Gene Therapy.

Bloomberg News (4/22, Waters) reports that 11 “years after the death of an 18-year-old boy led to the suspension of some trials and close scrutiny by regulators,” gene therapy “is experiencing a revival among scientists and drugmakers led by Genzyme and Pfizer Inc. in the US and Novartis AG in Europe.” And, “preliminary successes against brain and eye disorders are helping to spur the renewed interest.” At present, “there are…189 companies developing gene therapies, an increase from 44 in 1995,” and “US approvals for gene therapy will start coming in about four years and the first one cleared may be for a hereditary eye disease, predicted Philip Reilly, Genetix’s chief medical officer.”

For more information on eye and vision disorders visit


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: